4403 related articles for article (PubMed ID: 19744291)
1. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
[TBL] [Abstract][Full Text] [Related]
2. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
4. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
[TBL] [Abstract][Full Text] [Related]
5. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
[TBL] [Abstract][Full Text] [Related]
6. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
[TBL] [Abstract][Full Text] [Related]
7. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
[TBL] [Abstract][Full Text] [Related]
8. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
[TBL] [Abstract][Full Text] [Related]
9. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
[TBL] [Abstract][Full Text] [Related]
10. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V.
Mycka JM; Dellamano R; Kolassa EM; Wonder M; Ghosh S; Hay JW; Smeeding J
Value Health; 2010; 13(1):25-7. PubMed ID: 19883402
[TBL] [Abstract][Full Text] [Related]
11. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
Berger ML; Mamdani M; Atkins D; Johnson ML
Value Health; 2009; 12(8):1044-52. PubMed ID: 19793072
[TBL] [Abstract][Full Text] [Related]
12. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
13. The International Liaison Committee on Resuscitation (ILCOR) consensus on science with treatment recommendations for pediatric and neonatal patients: pediatric basic and advanced life support.
International Liaison Committee on Resuscitation
Pediatrics; 2006 May; 117(5):e955-77. PubMed ID: 16618790
[TBL] [Abstract][Full Text] [Related]
14. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III.
Mansley EC; Carroll NV; Chen KS; Shah ND; Piech CT; Hay JW; Smeeding J
Value Health; 2010; 13(1):14-7. PubMed ID: 19883404
[TBL] [Abstract][Full Text] [Related]
15. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
[TBL] [Abstract][Full Text] [Related]
16. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
[TBL] [Abstract][Full Text] [Related]
17. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.
Johnson ML; Crown W; Martin BC; Dormuth CR; Siebert U
Value Health; 2009; 12(8):1062-73. PubMed ID: 19793071
[TBL] [Abstract][Full Text] [Related]
18. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
19. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force.
Matza LS; Patrick DL; Riley AW; Alexander JJ; Rajmil L; Pleil AM; Bullinger M
Value Health; 2013 Jun; 16(4):461-79. PubMed ID: 23796280
[TBL] [Abstract][Full Text] [Related]
20. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
